

Under the auspices of



Melanoma
World Society
MWS

Congress Presidents
Axel Hauschild, Kiel, Germany
Claus Garbe, Tuebingen, Germany

2025 in Hamburg

15th European Post-Chicago Melanoma / Skin Cancer Meeting

Hamburg | Germany
Radisson Blu Hotel

european-post-chicago-meeting.org

June
26th–27th
2025

**Final
Program**

updated: 26/06/2025

CONTENT

»» WELCOME MESSAGE 03

»» PROGRAM AT A GLANCE 04

»» PROGRAM 07

Thursday, June 26th, 2025 07

Friday, June 27th, 2025 10

»» CONGRESS FACULTY 14

»» SATELLITE SYMPOSIA OVERVIEW 18

»» FLOOR PLAN 20

»» GENERAL INFORMATION 22

»» SPONSORS 24

WELCOME MESSAGE

Dear colleagues and friends,

We are excited to warmly welcome you to the Interdisciplinary Global Conference on News in Melanoma/Skin Cancer – the “European Post-Chicago Meeting”! After many successful years in Munich, we are thrilled to now host the event in the vibrant city of Hamburg, Germany.

This conference offers a comprehensive and interactive platform, delivering in-depth insights into the latest developments in melanoma diagnostics and therapy, while fostering direct dialogue with the world’s leading experts.

With our move to Hamburg, we are opening a new chapter for the conference. In this dynamic and historic city, we continue our tradition of active exchange among clinicians, researchers, and industry representatives. The 2025 conference features international key opinion leaders presenting cutting-edge research, sharing the latest clinical trial results, and engaging in thought-provoking discussions on emerging therapies.

Welcome to Hamburg – where you gain valuable scientific insights and connect with peers in a warm, familiar environment.

Best regards,



Axel Hauschild, MD
Congress President



Claus Garbe, MD
Congress President

PROGRAM AT A GLANCE

THURSDAY, JUNE 26th, 2025

	NEW YORK	SYDNEY
8:00	Opening of the conference	
	SYMPOSIUM I My personal highlights at ASCO 2025	
9:00		
	KEYNOTE LECTURE I	
10:00	SATELLITE SYMPOSIUM I	
	BREAK	
11:00	SATELLITE SYMPOSIUM II	
12:00	SYMPOSIUM II Attacking tumor cells	
13:00		
	BREAK	
14:00	SATELLITE SYMPOSIUM III	
15:00	SYMPOSIUM III Prognostic and predictive biomarkers	PARALLEL SYMPOSIUM I Registry data and studies: Update 2025
16:00	BREAK	
	SYMPOSIUM IV Neoadjuvant/perioperative treatment for skin cancer	
17:00		PARALLEL SYMPOSIUM II Cutaneous T-cell lymphoma (CTCL)
	SYMPOSIUM V Adverse event management for ICI	
18:00		
19:00		

FRIDAY, JUNE 27th, 2025

	NEW YORK	SYDNEY
8:00	SYMPOSIUM VI Adjuvant treatment of melanoma	PARALLEL SYMPOSIUM III Complex melanoma cases
9:00	SYMPOSIUM VII What's new in guidelines and studies for...	PARALLEL SYMPOSIUM IV Complex non-melanoma cases
10:00	SYMPOSIUM VIII ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas	
11:00	SATELLITE SYMPOSIUM IV	
	BREAK	
12:00	KEYNOTE LECTURE II	
	KEYNOTE LECTURE III	
13:00	LUNCH SATELLITE SYMPOSIUM V	
	SATELLITE SYMPOSIUM VI	
14:00	BREAK	
	SYMPOSIUM IX Is adjuvant treatment for melanoma dead?	
15:00	SYMPOSIUM X Melanoma survivorship	
	CLOSING REMARKS	
16:00		
17:00		
18:00		
19:00		

Save the Date

**June
25th–26th
2026**

**Hamburg | Germany
Radisson Blu Hotel**

2026 in Hamburg

16th European Post-Chicago Melanoma/Skin Cancer Meeting

Congress Presidents

Axel Hauschild, Kiel, Germany
Christoffer Gebhardt, Hamburg, Germany



SAVE THE DATES 2026

**SAVE
THE
DATE**

14th EUROPEAN SCHOOL OF DERMATO-ONCOLOGY

AN INTERACTIVE COURSE MEETING

JUNE 26TH-27TH, 2026

**RADISSON BLU HOTEL
HAMBURG, GERMANY**



Course Directors

Axel Hauschild, Kiel, Germany
Christoffer Gebhardt, Hamburg, Germany

THURSDAY, JUNE 26th, 2025

08:00

NEW YORK

OPENING OF THE CONFERENCE

CLAUS GARBE, TUEBINGEN, GERMANY

08:10–09:30

NEW YORK

SYMPOSIUM I

My personal highlights at ASCO 2025

CHAIRPERSONS: MERRICK I. ROSS, HOUSTON, USA
JOSEP MALVEHY, BARCELONA, SPAIN

08:10–08:45 ...in melanoma

Sapna Patel, Denver, USA

08:50–09:25 ... in non-melanoma skin cancer

Céleste Lebbé, Paris, France

09:30–10:00

NEW YORK

KEYNOTE LECTURE I

CHAIRPERSON: CAROLINE ROBERT, PARIS, FRANCE

Cellular Therapies for melanoma

John Haanen, Amsterdam, Netherlands

10:00–10:45

NEW YORK

SATELLITE SYMPOSIUM I

SEE PROGRAM ON PAGE 18

10:45–11:00

BREAK

11:00–12:00

NEW YORK

SATELLITE SYMPOSIUM II

SEE PROGRAM ON PAGE 18

12:00–13:00

NEW YORK

SYMPOSIUM II

Attacking tumor cells

CHAIRPERSONS: JOHN HAANEN, AMSTERDAM, NETHERLANDS
OLIVIER MICHELIN, GENEVA, SWITZERLAND

12:00–12:15 How vaccines work

Olivier Michielin, Geneva, Switzerland

12:20–12:35 T cell engagers

Dirk Schadendorf, Essen, Germany

12:40–12:55 How to increase T cell fitness to improve immunotherapy?

Caroline Robert, Paris, France

THURSDAY, JUNE 26th, 2025

13:00–14:00

BREAK

14:00–15:00

NEW YORK

SATELLITE SYMPOSIUM III

SEE PROGRAM ON PAGE 18

15:00–16:00

NEW YORK

SYMPOSIUM III

Prognostic and predictive biomarkers

CHAIRPERSONS: DIRK SCHADENDORF, ESSEN, GERMANY
CHRISTOPH HOELLER, VIENNA, AUSTRIA

15:00–15:15 Gene Expression Profiling for melanoma primaries
Teresa Amaral, Tuebingen, Germany

15:15–15:30 Nomograms for stage II-IV melanoma
Alexander van Akkooi, Sydney, Australia

15:30–15:45 Liquid biopsy for melanoma: ready for primetime?
Christoffer Gebhardt, Hamburg, Germany

15:45–16:00 Discussion

15:00–17:00

SYDNEY

PARALLEL SYMPOSIUM I

Registry data and studies: Update 2025

CHAIRPERSONS: LIDIJA KANDOLF, BELGRADE, SERBIA
PETER MOHR, BUXTEHUDE, GERMANY

15:00–15:15 Real-world data: BCC studies
Josep Malvehy, Barcelona, Spain

15:15–15:30 Real-world data: SCC studies
Ulrike Leiter-Stoeppke, Tuebingen, Germany

15:30–15:45 Real-world data: rare cancers
Céleste Lebbé, Paris, France

15:45–16:00 Real-world data: adjuvant melanoma studies
Eva Ellebaek Steensgaard, Copenhagen, Denmark

16:00–16:15 Real-world data: metastatic melanoma studies
Michael Weichenthal, Kiel, Germany

16:15–16:30 SERIO registry update
Lucie Heinzerling, Munich, Germany

16:30–16:45 Access to medicines for melanoma in Europe
Lidija Kandolf, Belgrade, Serbia

16:45–17:00 Discussion

THURSDAY, JUNE 26th, 2025

16:00–16:15

BREAK

16:15–17:15

NEW YORK

SYMPOSIUM IV

Neoadjuvant/perioperative treatment for skin cancer

CHAIRPERSONS: KAI-MARTIN THOMS, GOETTINGEN, GERMANY
ALEXANDER VAN AKKOOI, SYDNEY, AUSTRALIA

16:15–16:30 ICI combinations for melanoma

Alexander van Akkooi, Sydney, Australia

16:35–16:50 Perioperative treatment for melanoma

Merrick I. Ross, Houston, USA

16:55–17:10 Neoadjuvant treatment for NMSC

Jessica Hassel, Heidelberg, Germany

17:15–18:15

NEW YORK

SYMPOSIUM V

Adverse event management for ICI

CHAIRPERSONS: JESSICA HASSEL, HEIDELBERG, GERMANY
LISA ZIMMER, ESSEN, GERMANY

17:15–17:30 What drives autoimmune adverse events?

Lukas Flatz, Tuebingen, Germany

17:35–17:50 Systemic corticosteroids – friend or foe?

Helen Gogas, Athens, Greece

17:55–18:10 ICI in preexisting autoimmune diseases

Ralf Gutzmer, Minden, Germany

17:00–18:00

SYDNEY

PARALLEL SYMPOSIUM II

Cutaneous T-cell lymphoma (CTCL)

CHAIRPERSONS: CHALID ASSAF, KREFELD, GERMANY
EMMANUELLA GUENOVA, LINZ, SWITZERLAND

17:15–17:30 Medical needs in CTCL

Pietro Quaglino, Turin, Italy

17:35–17:50 First-line treatment: standards and trials

Emmanuella Guenova, Linz, Switzerland

17:55–18:10 Later-line treatment: standards and trials

Chalid Assaf, Krefeld, Germany

FRIDAY, JUNE 27th, 2025

08:00–09:00

NEW YORK

SYMPOSIUM VI

Adjuvant treatment of melanoma

CHAIRPERSONS: HELEN GOGAS, ATHENS, GREECE
RALF GUTZMER, MINDEN, GERMANY

08:00–08:15 Which benefit justifies adjuvant treatment in stage II/III
(NNT, number needed to treat)

Alexander Eggermont, Utrecht, Netherlands

08:20–08:35 However, adjuvant treatment goes along with adverse events
(NNH, number needed to harm)

Elisabeth Livingstone, Essen, Germany

08:40–08:55 Are patients with acral melanomas good
candidates for adjuvant treatment?

Paul Nathan, Northwood, United Kingdom

08:00–09:00

SYDNEY

PARALLEL SYMPOSIUM III

Complex melanoma cases

CHAIRPERSONS: MIRIAM MENGONI, LUEBECK, GERMANY
ZELJKO MIJUSKOVIC, BELGRADE, SERBIA
LAURA SUSOK, DORTMUND, GERMANY
ULRIKE LEITER-STOEPPKE, TUEBINGEN, GERMANY

08:00–08:15 Case 1

Zeljko Mijuskovic, Belgrade, Serbia

08:15–08:30 Case 2

Miriam Mengoni, Luebeck, Germany

08:30–08:45 Case 3

Laura Susok, Dortmund, Germany

08:45–09:00 Case 4

Ulrike Leiter-Stoeppke, Tuebingen, Germany

09:00–10:00

NEW YORK

SYMPOSIUM VII

What's new in guidelines and studies for...

CHAIRPERSONS: KETTY PERIS, ROME, ITALY
VISHAL PATEL, WASHINGTON, USA

09:00–09:18 ... basal cell carcinoma

Ketty Peris, Rome, Italy

09:18–09:36 ... squamous cell carcinoma

Vishal Patel, Washington, USA

09:36–09:54 ... other skin malignancies

Philippe Saiag, Paris, France

FRIDAY, JUNE 27th, 2025

09:00–10:00

SYDNEY

PARALLEL SYMPOSIUM IV

Complex non-melanoma cases

CHAIRPERSONS: PETR ARENBERGER, PRAGUE, CZECH REPUBLIC
ANA MARIA FORSEA, BUCHAREST, ROMANIA
DAGMAR VON BUBNOFF, LUEBECK, GERMANY

09:00–09:20 Case 1

Petr Arenberger, Prague, Czech Republic

09:20–09:40 Case 2

Ana Maria Forsea, Bucharest, Romania

09:40–10:00 Case 3

Dagmar von Bubnoff, Luebeck, Germany

10:00–10:45

NEW YORK

SYMPOSIUM VIII

ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas

CHAIRPERSON: JAMES LARKIN, SUTTON, UNITED KINGDOM

10:00–10:15 Experiences from a high-volume ImmTAC center

Christoffer Gebhardt, Hamburg, Germany

10:15–10:35 Tebentafusp, Brenetafusp and other ImmTACs not only for uveal melanomas

Paul Nathan, Northwood, United Kingdom

10:35–10:45 Discussion

10:45–11:30

NEW YORK

SATELLITE SYMPOSIUM IV

SEE PROGRAM ON PAGE 19

11:30–11:45

BREAK

11:45–12:15

NEW YORK

KEYNOTE LECTURE II

CHAIRPERSON: PAUL NATHAN, NORTHWOOD, UNITED KINGDOM

Metastatic uveal melanoma – future perspectives

Josep Maria Piulats Rodriguez, Barcelona, Spain

FRIDAY, JUNE 27th, 2025

12:15–12:45

NEW YORK

KEYNOTE LECTURE III

CHAIRPERSON: DIRK SCHADENDORF, ESSEN, GERMANY

Diets for cancer patients: are they worthwhile?

Alpaslan Tasdogan, Essen, Germany

12:45–13:30

NEW YORK

LUNCH SATELLITE SYMPOSIUM V

SEE PROGRAM ON PAGE 19

13:30–14:00

NEW YORK

SATELLITE SYMPOSIUM VI

SEE PROGRAM ON PAGE 19

14:00–14:15

BREAK

14:15–15:05

NEW YORK

SYMPOSIUM IX

Is adjuvant treatment for melanoma dead?

CHAIRPERSONS: OLIVIER MICHIELIN, GENEVA, SWITZERLAND
CLAUS GARBE, TUEBINGEN, GERMANY

14:15–14:30 Yes

Berenice Lang, Frankfurt, Germany

14:30–14:45 No

Mario Mandala, Perugia, Italy

14:45–15:05 Panel Discussion

15:05–15:45

NEW YORK

SYMPOSIUM X

Melanoma survivorship

CHAIRPERSONS: ELISABETH LIVINGSTONE, ESSEN, GERMANY
MERRICK I. ROSS, HOUSTON, USA

15:05–15:20 Melanoma survival steadily increases

Lisa Zimmer, Essen, Germany

15:25–15:40 Quality of life, complaints and needs

Andrea Forschner, Tuebingen, Germany

15:45

NEW YORK

CLOSING REMARKS

AXEL HAUSCHILD, KIEL, GERMANY

Congress On-Demand

All approved lectures will be available on the On-Demand platform from July 1, 2025 until September 30, 2025.

The on-demand service is available to all registered attendees (F2F and virtual).

**THE AREA
IS PASSWORD
PROTECTED**

Access to the On-Demand area is granted using the same login credentials as for the virtual platform.

CONGRESS FACULTY

A

Teresa Amaral, MD

Senior Physician, Dermatology
University Hospital Tuebingen
Liebermeisterstraße 25
72076 Tuebingen, Germany

Petr Arenberger, MD

Professor of Dermatology
Charles University Prague
Šrobárova 50
100 34 Prague, Czech Republic

Chalid Assaf, MD

Head Physician, Dermatology
Helios Klinikum Krefeld
Lutherplatz 40
47805 Krefeld, Germany

E

Alexander Eggermont, MD

General Director
Princess Máxima Center for Pediatric Oncology
Heidelberglaan 25
3584 CS Utrecht, Netherlands

F

Lukas Flatz, MD

Senior Physician, Dermatology
University Hospital Tuebingen
Liebermeisterstraße 25
72076 Tuebingen, Germany

Andrea Forschner, MD

Head of Melanoma Outpatient Clinic
University Hospital Tuebingen
Liebermeisterstraße 25
72076 Tuebingen, Germany

Ana Maria Forsea, MD

Professor of Dermatology
Carol Davila University of Medicine
Dionisie Lupu 37
Bucharest, Romania

G

Claus Garbe, MD

Eberhard Karls University
University Hospital Tuebingen
Liebermeisterstraße 25
72076 Tuebingen, Germany

Christoffer Gebhardt, MD

Professor of Dermatology
University Medical Center Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg, Germany

Emmanuella Guenova, MD

Head, Clinical Department of Translational
Immunodermatology
Kepler University Hospital Linz
University Hospital of Dermatology and Venerology
Med Campus III., Krankenhausstraße 9
4021 Linz, Switzerland

Helen Gogas, MD

Professor of Medicine
National and Kapodistrian University of Athens
Panepistimiou 30
10679 Athens, Greece

Ralf Gutzmer, MD

Head Physician, Dermatology
Johannes Wesling Klinikum Minden
Hans-Nolte-Straße 1
32429 Minden, Germany

H

John Haanen, MD

Head, Department of Medical Oncology
Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam, Netherlands

Jessica Hassel, MD

Head, Dermato-Oncology
National Center for Tumor Diseases (NCT)
Im Neuenheimer Feld 460
69120 Heidelberg, Germany

Axel Hauschild, MD

Professor of Dermatology
University Hospital Schleswig-Holstein
Arnold-Heller-Straße 3
24105 Kiel, Germany

Lucie Heinzerling, MD

Head, Dermato-Oncology
LMU University Hospital
Skin Cancer Center at CCC Munich
Frauenlobstraße 9–11,
80337 Munich, Germany

Christoph Hoeller, MD

Department of Dermatology
Medical University of Vienna
Vienna, Austria

K

Lidija Kandolf, MD

Professor of Dermatology
Clinical Center of Serbia
Pasterova 2
11000 Belgrade, Serbia

L

Berenice Lang, MD

Coordinator of the Skin Cancer Center
Department of Dermatology, Venereology
and Allergology
University Hospital Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt am Main, Germany

James Larkin, MD

Head of The Royal Marsden Skin Unit
The Royal Marsden/Institute of Cancer Research
Downs Road, Sutton, Surrey, SM2 5PT
United Kingdom

Celeste Lebbé, MD

Professor of Dermatology
Hôpital Saint-Louis
1 Avenue Claude Vellefaux
75010 Paris, France

Ulrike Leiter-Stoeppke, MD

Head, Dermatology Department
University Hospital Tuebingen
Liebermeisterstraße 25
72076 Tuebingen, Germany

Elisabeth Livingstone, MD

Senior Physician, Dermatology
University Hospital Essen
Hufelandstraße 55
45147 Essen, Germany

M

Mario Mandalà, MD

Senior Researcher, Oncology
University of Perugia
Piazza Università
06123 Perugia, Italy

Josep Malvehy, MD

Director, Melanoma Unit
Hospital Clínic de Barcelona
Carrer de Villarroel, 170
08036 Barcelona, Spain

Miriam Mengoni, MD

Senior Consultant
University Medical Center
Schleswig-Holstein (UKSH)
Campus Lübeck
Department of Dermatology,
Allergology and Venereology
Ratzeburger Allee 160
23538 Luebeck
Germany

Olivier Michielin, MD

Head, Precision Medicine
Geneva University Hospitals
Rue Gabrielle-Perret-Gentil 4
1211 Geneva 14, Switzerland

Zeljko Mijuskovic, MD

Department of Dermatology
and Venereology
Faculty of Medicine,
Military Medical Academy
17 Crnotravska
Belgrade, Serbia

Peter Mohr, MD

Chief Physician, Dermatology
Elbe Klinikum Buxtehude
Am Krankenhaus 1
21614 Buxtehude, Germany

N

Paul Nathan, MD

Consultant Oncologist
Mount Vernon Cancer Centre
Rickmansworth Rd
Northwood HA6 2RN, United Kingdom

P

Sapna Patel, MD

Director, Melanoma Program
University of Colorado Cancer Center
13001 E 17th Pl, Aurora, CO 80045, USA

Vishal Patel, MD

Associate Professor of Dermatology at the
George Washington University School of
Medicine & Health Sciences
Associate Professor of Medicine (Oncology)
at GW Cancer Center
George Washington Medical Faculty Associates
2150 Pennsylvania Avenue NW, 2nd Floor
Washington, DC 20037, USA

Ketty Peris, MD

Director, Dermatology
Università Cattolica del Sacro Cuore
Largo Francesco Vito, 1
00168 Rome, Italy

Josep Maria Piulats Rodriguez, MD

Senior Researcher, Oncology
Hospital Clínic de Barcelona
Carrer de Villarroel, 170
08036 Barcelona, Spain

Q

Pietro Quaglino, MD

Associate Professor
Dermatologic Clinic, Department of
Medical Sciences, University of Turin,
Corso Bramante 88
10126 Turin, Italy

R

Caroline Robert, MD

Head, Dermatology Department
Gustave Roussy
114 Rue Edouard Vaillant
94800 Villejuif, France

Merrick I. Ross, MD

University of Texas
Department of Surgical Oncology,
Division of Surgery
Houston, USA

S

Dirk Schadendorf, MD

Director & Chair Department of
Dermatology & Director,
Comprehensive Cancer Center
University Hospital Essen & Research
Alliance Ruhr, Research Center One Health,
University Duisburg-Essen
Hufelandstraße 55
45147 Essen, Germany

Philippe Saiag, MD

Head, Dermatology Department
Hôpital Ambroise-Paré
9 Avenue Charles de Gaulle,
92100 Boulogne-Billancourt, France

Eva Ellebaek Steensgaard, MD

National Center for Cancer
Immune Therapy, CCIT-DK
Head of the Clinic; Melanoma,
Pancreatic Cancer, and Phase 1 Unit
Department of Oncology
Copenhagen University Hospital, Herlev
Borgmester Ib Juuls Vej 11, 2730 Herlev
Denmark

Laura Susok, MD

Director, Department of Dermatology
Klinikum Dortmund
Muensterstraße 240
44145 Dortmund, Germany

T

Alpaslan Tasdogan, MD

Professor of Dermatology and Tumor Metabolism
University Hospital Essen
Hufelandstraße 55
45147 Essen, Germany

Kai-Martin Thoms, MD

Head, Skin Cancer Center
and Dermatologic Surgery
Department of Dermatology,
Venereology and Allergology
University Medical Center Goettingen
Robert-Koch-Straße 40
37075 Goettingen, Germany

V

Alexander van Akkooi, MD

Head, Melanoma and Skin Cancer Center
Melanoma Institute Australia
40 Rocklands Rd
North Sydney NSW 2060, Australia

Dagmar von Bubnoff, MD

Professor of Dermatology
Deputy Director of the Clinic
Head of the Allergy Department
Department of Allergology and Drug-Based Tumor
Therapy
University Medical Center Schleswig-Holstein
Clinic for Dermatology, Allergology, and Venereology
Ratzeburger Allee 160
23538 Luebeck, Germany

W

Michael Weichenthal, MD

Professor of Dermatology
University Hospital Schleswig-Holstein
Arnold-Heller-Straße 3
24105 Kiel, Germany

Z

Lisa Zimmer, MD

Senior Physician, Oncology
University Hospital Essen
Hufelandstraße 55
45147 Essen, Germany

SATELLITE SYMPOSIA OVERVIEW

THURSDAY, JUNE 26th, 2025

-
- 10:00–10:45 **SATELLITE SYMPOSIUM I**
REPLIMUNE Gold Sponsor
Optimizing Treatment for Skin Cancers in Immunocompromised Patients
CHAIR: AXEL HAUSCHILD, KIEL, GERMANY
- 10:00–10:05 Introduction
[Axel Hauschild, Kiel, Germany](#)
- 10:05–10:20 Skin Cancer Risks in the Post-Transplant Setting
[Alexander van Akkooi, Sydney, Australia](#)
- 10:20–10:35 Treatment Paradigms for Post-Transplantation Cutaneous Malignancies
[Christoffer Gebhardt, Hamburg, Germany](#)
- 10:35–10:45 Discussion, Q&A and Conclusions
[Axel Hauschild, Kiel, Germany](#)
-
- 11:00–12:00 **SATELLITE SYMPOSIUM II**
REGENERON Platinum Sponsor
Advancing Immunotherapy in Patients with Cutaneous Squamous Cell Carcinoma (CSCC) at Risk of Recurrence
CHAIR: AXEL HAUSCHILD, KIEL, GERMANY
- Topics:**
- Defining high-risk features in patients with CSCC at risk of recurrence
 - Evaluating adjuvant immunotherapy in patients with high-risk CSCC
 - Exploring immunotherapy approaches in neoadjuvant, adjuvant, and perioperative settings
- [Christoffer Gebhardt, Hamburg, Germany](#)
[Vishal Patel, Washington, USA](#)
-
- 14:00–15:00 **SATELLITE SYMPOSIUM III**
MSD Platinum Sponsor
**Navigating early-stage melanoma:
Evolution of adjuvant treatment outcomes and future directions**
- 14:00–14:05 Welcome and opening remarks
[Axel Hauschild, Kiel, Germany](#)
- 14:05–14:25 Treatment evolution to prevent recurrence in early-stage melanoma:
Time to look back/ahead 5-min. Q&A
[Dirk Schadendorf, Essen, Germany](#)
- 14:25–14:40 Clinical cases and panel discussion
[Merrick Ross, Houston, USA](#)
- 14:40–14:55 Integrating novel treatment modalities in the adjuvant setting 5-min. Q&A
[Christoffer Gebhardt, Hamburg, Germany](#)
- 14:55–15:00 Closing remarks
[Axel Hauschild, Kiel, Germany](#)


FRIDAY, JUNE 27th, 2025

-
- 10:45–11:30 SATELLITE SYMPOSIUM IV
BMS Gold Sponsor
**Evolving Frontiers in Melanoma 2025:
A Visionary Panel on Progress and Promise**
CHAIR AND EXPERT PENALIST: AXEL HAUSCHILD, KIEL, GERMANY
EXPERT PENALIST: CHRISTOPH HOELLER, VIENNA, AUSTRIA
JAMES LARKIN, SUTTON, UNITED KINGDOM
-
- 12:45–13:30 LUNCH SATELLITE SYMPOSIUM V
SunPharma Gold Sponsor
**Neoadjuvant therapy for resectable stage III melanoma in 2025:
Current Evidence**
CHAIR: AXEL HAUSCHILD, KIEL, GERMANY
Welcome and Introduction
[Axel Hauschild, Kiel, Germany](#)
Theoretical part:
Current published evidence on the neoadjuvant approach in stage III melanoma
[Axel Hauschild, Kiel, Germany](#)
Clinical part:
Clinical Case
[Paul Nathan, Northwood, United Kingdom](#)
Clinical Case
[Alexander Van Akkooi, Sydney, Australia](#)
Discussion
[All](#)
Closure
[Axel Hauschild, Kiel, Germany](#)
-
- 13:30–14:00 SATELLITE SYMPOSIUM VI
MERCK
SPEAKER: AXEL HAUSCHILD, KIEL, GERMANY
**Real-World Perspectives: Outcomes and Clinical
Practice Lessons from Treating Advanced Merkel Cell Carcinoma**


FLOOR PLAN

RADISSON BLU HOTEL HAMBURG

FIRST FLOOR



SECOND FLOOR



GENERAL INFORMATION

CME Credits

Accreditation by the EACCME® confers the right to place the following statement in all communication materials including the event website, the event programme and the certificate of attendance. The following statements must be used without revision: "The 15th European Post-Chicago Melanoma/Skin Cancer Meeting, Hamburg, Germany 26/06/2025–27/06/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity."

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Breakdown of ECMEC®s per day	Date Credit:
26/06/2025	5.5
27/06/2025	5.5

Congress Date

June 26th–June 27th, 2025

Congress Organization



Gesellschaft für medizinische Projekte mbH
Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany
info@medconcept.org | www.medconcept.org
Phone +49 (0)3342 42689-30 | Fax +49 (0)3342 42689-40

Congress Venue

Radisson Blu Hotel Hamburg
Congresspl. 2, 20355 Hamburg, Germany
Phone: +49 (0)40 3502 3100 | E-Mail: info.hamburg@radissonblu.com

Exhibition

A commercial exhibition will be held at the congress venue, close to the main rooms.

Exhibition Opening Hours

Thursday, June 26 th , 2025	07:30–18:30
Friday, June 27 th , 2025	07:30–18:00

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements with respect to health and travel insurance.

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration and Information Desk

The registration desk is situated at the ground floor of the Radisson Blu Hotel to the right of the reception and in front of the meeting area entrance.

Registration Desk Opening Hours

Thursday, June 26th, 2025 07:00–19:00

Friday, June 27th, 2025 07:30–18:00

Registration Fees

Virtual packages and on-demand service is included in all ticket categories.

	Presence Tickets			Virtual Tickets
	Early Bird until May 1 st , 2025	Regular Fee until June 16 th , 2025	Late	
Full Delegate Ticket	400 euros	500 euros	600 euros	400 euros
EADO Members	300 euros	400 euros	500 euros	300 euros
Students/Nurses Ticket*	150 euros	200 euros	250 euros	150 euros
Eastern European Countries*	150 euros	200 euros	250 euros	150 euros
Residents*	150 euros	200 euros	250 euros	150 euros

*Please upload proof of university or clinic for students/nurse ticket, and proof of residence in a european eastern country for reduced tickets of this category, during registration process.

SPONSORS

PLATINUM



REGENERON

GOLD



SILVER



BRONZE

IMMUNOCORE

EXHIBITORS AND SPONSORS



Advancing Immunotherapy in Patients with Cutaneous Squamous Cell Carcinoma (CSCC) at Risk of Recurrence

Thursday, 26 June 2025
11:00–12:00 CEST

Room: New York
Radisson Blu Hotel, Hamburg

Topics

- Defining high-risk features in patients with CSCC at risk of recurrence
- Evaluating adjuvant immunotherapy in patients with high-risk CSCC
- Exploring immunotherapy approaches in neoadjuvant, adjuvant, and perioperative settings



Chair
Prof. Axel Hauschild
Germany

Prof. Christoffer Gebhardt
Germany



Prof. Vishal Patel
United States

This symposium is intended for healthcare professionals only. It has been organised and fully sponsored by Regeneron Pharmaceuticals Inc.

Navigating early-stage melanoma: Evolution of adjuvant treatment outcomes and future directions

Radisson Blu Hotel • Room: New York
Hamburg, Germany

Thursday, 26 June 2025
14:00 – 15:00 (CEST)

Chair



Axel Hauschild

Professor and Head
Dermato-oncology
Department
University of Kiel
Kiel, Germany

Faculty



Christoffer Gebhardt

Professor of Dermatooncology
and Experimental Dermatology
University Medical Center
Hamburg-Eppendorf (UKE)

Head, University Skin Cancer
Center Hamburg
Vice Chair, Department of
Dermatology
Head, Fleur Hiege Center for
Skin Cancer Research
Hamburg, Germany



Merrick Ross

Professor of Surgery
Chief, Melanoma Section
Department of Surgical
Oncology
University of Texas
MD Anderson Cancer Center
Houston, Texas, USA



Dirk Schadendorf

Director, Department of
Dermatology and the
West German Cancer
Center (WTZ)
University Hospital Essen
Essen, Germany

Agenda

14:00 – 14:05

Welcome and opening remarks
Axel Hauschild

14:05 – 14:25

Treatment evolution to prevent
recurrence in early-stage melanoma:
Time to look back/ahead
5-min. Q&A
Dirk Schadendorf

14:25 – 14:40

Clinical cases and panel discussion
Merrick Ross

14:40 – 14:55

Integrating novel treatment
modalities in the adjuvant setting
5-min. Q&A
Christoffer Gebhardt

14:55 – 15:00

Closing remarks
Axel Hauschild

Satellite symposium sponsored by MSD

This program is not intended for healthcare professionals who practice in, are licensed to practice in, or reside in the U.S., its territories, or Puerto Rico.

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. HQ-NON-01385 06/25 W6599794





REZIDIVFREIHEIT BEDEUTET FÜR MICH ZUKUNFT.

OPDIVO® adjuvant im Melanom Stadium IIB/C –
weil Heilung einen guten Start braucht.



Mehr erfahren

 Bristol Myers Squibb®

OPDIVO®
(nivolumab)

OPDIVO® 10 mg/ml Konzentrat z. Herst. e. Infusionslösung. **Wirkstoff:** Nivolumab. **Sonst. Bestandteile:** Natriumcitratdihydrat, Natriumchlorid, Mannitol, Pentetsäure, Polysorbat 80, Natriumhydroxid, Salzsäure u. Wasser f. Injektionszwecke. **Anw.:** Als Monother. b. Erw. u. Jugendl. ab 12 J. f. d. Behandl. d. fortgeschritt. (nicht resezierb. od. met.) Melanoms. Als Monother. b. Erw. u. Jugendl. ab 12 J. zur adjuv. Behandl. d. Melanoms im Stadium IIB od. IIC od. d. Melanoms mit Lymphknotenbeteilig. od. Metastasierg. nach vollst. Resektion. Als Monother. zur Behandl. d. lokal fortgeschritt. od. met. NSCLC nach vorheriger CTx b. Erw. Als Monother. b. Erw. zur Behandl. d. fortgeschritt. RCC nach Vorther. Als Monother. zur Behandl. d. rezidiv. od. refrakt. cHL b. Erw. nach ASCT u. Behandl. m. Brentuximab Vedotin. Als Monother. zur Behandl. d. rezidiv. od. met. Plattenepithelkarzinoms d. Kopf-Hals-Bereichs b. Erw. mit Progress. während od. nach Pt-basierter Ther. Als Monother. zur Behandl. d. lokal fortgeschritt. nicht resezierb. od. met. Urothelkarzinoms b. Erw. nach Versagen vorheriger Pt-haltiger Ther. Als Monother. zur adjuv. Behandl. d. MIBC mit Tumorzell-PD-L1-Expression $\geq 1\%$ b. Erw. mit hohem Rezidivrisiko nach radikaler Resekt. d. MIBC. Als Monother. zur Behandl. d. nicht resezierb. fortgeschritt. rezidiv. od. met. Plattenepithelkarzinoms d. Ösophagus b. Erw. nach vorheriger fluoropyrimidin- u. Pt-basierter Komb.-CTx. Als Monother. zur adjuv. Behandl. d. Karzinome d. Ösophagus od. d. gastroösophag. Übergangs b. Erw. mit patholog. Resterkr. nach vorheriger neoadjuv. Chemoradiother. **Gegenanz.:** Überempf.-keit gg. d. Wirkstoff od. sonst. Bestandt. **Nebenwirk.:** **Sehr häufig:** Infekt. d. oberen Atemwege; Lymphopenie; Anämie; Leukopenie; Neutropenie; Thrombozytopenie; vermind. Appetit; Hyperglykämie; Kopfschm.; Dyspnoe; Husten; Diarrhö; Erbr.; Übelk.; Abdominalschm.; Obstipation; Ausschlag; Pruritus; Muskel- u. Skelettschm.; Arthralgie; Fatigue; Fieber; Anstieg AST; Hyponatriämie; Hypoalbuminämie; Anstieg alkal. Phosphatase, Kreatinin, ALT, Lipase; Hyperkälämie; Anstieg Amylase; Hypokalziämie; Hypomagnesiämie; Hypokaliämie; Hyperkalziämie. **Häufig:** Pneumonie; Bronchitis; Infusionsbed. Reakt. (einschl. Zytokin-Freisetzungssyndr.); Überempfindlichk. (einschl. anaphylakt. Reakt.); Hypothyreose; Hyperthyroidismus; Thyroiditis; Dehydr.; Gew.-Verlust; Hypoglykämie; periph. Neuropathie; Schwindelgef.; verschwomm. Sehen; trock. Augen; Tachykard.; Vorhofflimm.; Hypertonie; Pneumonitis; Pleuraerguss; Kolitis; Stomatitis; trock. Mund; Vitiligo; trock. Haut; Erythem; Alopezie; Arthritis; Nierenvers. (einschl. akuter Nierenschäd.); Schm.; Schm. in d. Brust; Ödeme; Anstieg Gesamtbilirubin; Hypernatriämie; Hypermagnesiämie. **Gelegentl.:** Eosinophilie; Sarkoidose; Nebenniereninsuff.; Hypophyseninsuff.; Hypophysitis; Diabetes mell.; metabol. Azidose; Polyneuropathie; autoimm. Neuropathie (einschl. Gesichtsnerv- u. Abduzensparese); Uveitis; Myokarditis; perikard. Erk.; Arrhythmie (einschl. ventrik. A.); Lungeninfiltr.; Pankreatitis; Gastritis; Hepatitis; Cholestase; Psoriasis; Rosazea; Erythema multiforme; Urtikaria; rheumat. Polymyalgie. **Selten:** Asept. Meningitis; Histiozytar nekrotisier. Lymphadenitis (Kikuchi-L.); diab. Ketoazidose; Hypoparathyreoidismus; Guillain-Barré-Syndr.; Demyelinisier.; myasthenes Syndr.; Enzephalitis; Optikusneuritis; Vaskulitis; Zwölffingerdarmgeschw.; exokrine Pankreasinsuff.; Zöliakie; tox. epiderm. Nekrolyse; Stevens-Johnson-Syndr.; Sjögren-Syndr.; Myopathie; Myositis (einschl. Polym.); Rhabdomyolyse; tubulointerst. Nephritis; nicht-infektiöse Zystitis. **Nicht bekannt:** Hämophagozyt. Lymphohistiolyse; Abstoß. solides Organtransplantat; Tumorlyse-Syndr.; Vogt-Koyanagi-Harada-Syndr.; Lichen sclerosus; and. Lichenerkrank.; Myelitis (einschl. transverse M.). Weitere Hinweise siehe Fachinformation. Verschreibungspflichtig. Pharmazeutischer Unternehmer: Bristol-Myers Squibb Pharma EEIG; Plaza 254; Blanchardstown Corporate Park 2; Dublin 15; D15 T867; Irland. Stand: v34.

Every time we care for a single person, we make the whole world better.



New ways to care.

At Pierre Fabre Laboratories, we have a passion for addressing clinical challenges through innovative solutions, keeping patients at the core of our efforts.

The fight against cancer is our main priority in medical care.

We take a holistic approach to cancer care focusing not only on treatment, but also prevention and support.



LABORATOIRES

Pierre Fabre

Please visit our booth located across from the New York Hall



Replimune®

Our mission is to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies

The RPx platform is intended to ignite a local and systemic response to cancer

We imagine a world where cancer is a curable disease,



Neoadjuvant therapy for resectable stage III melanoma in 2025: Current Evidence

SUN PHARMA SYMPOSIUM AGENDA

WELCOME & INTRODUCTION		Prof. Axel Hauschild University Hospital Schleswig-Holstein, Campus Kiel, Germany
THEORETICAL PART		
Speaker	Prof. Axel Hauschild	Current published evidence on the neoadjuvant approach in stage III melanoma
CLINICAL PART		
Speaker	Prof. Paul Nathan Mount Vernon Cancer Centre, UK	Clinical Case 1
Speaker	Prof. Alexander Van Akkooi Melanoma Institute Australia, Australia	Clinical Case 2
DISCUSSION		All
CLOSURE		Prof. Axel Hauschild

DATE/TIME

Friday, June 27, 2025
12:45 to 13:30 h

LOCATION

The New York Room



Prof. Axel Hauschild



Prof. Paul Nathan



Prof. Alexander Van Akkooi



Reaching People. Touching lives.

JAVELIN MERKEL 200 TRIAL DURABLE RESPONSE IN MERKEL CELL CARCINOMA¹⁻³ AND EXTENDED OS AFTER >4 YEARS OF FOLLOW-UP^{2,3*}



REAL-WORLD DATA AVAILABLE IN **OVER 600 PATIENTS WITH mMCC IN TOTAL**
SUPPORT AND SUPPLEMENT THE DURABLE RESPONSES AND PROLONGED SURVIVAL
SEEN IN CLINICAL TRIAL DATA.⁴⁻¹²



*>4 years in 1L and >5 years in 2L+.

†ORRs reported across RW studies in ~450 patients. Range of ORRs: 45% to 68%.⁴⁻⁸

‡OS outcomes reported across RW studies in ~200 patients. Range of median OS: 16.0 to 52.0 months.^{6,7,11,12}

BAVENCIO® is indicated as monotherapy for the treatment of adult patients with mMCC.¹

Zum Pflichttext

1L=first-line; 2L+=second-line or later; mMCC=metastatic Merkel cell carcinoma; ORR=objective response rate; OS=overall survival; RW=real-world.

References: 1. BAVENCIO® EU SmPC, March 2025. 2. D'Angelo SP, et al. *ESMO Open*. 2021;6(6):100290. 3. D'Angelo SP, et al. *ESMO Open*. 2024;9(5):103461. 4. Walker JW, et al. *J Immunother Cancer*. 2020;8(1):e000313. 5. Levy S, et al. *J Immunother Cancer*. 2020;8(2):e001076. 6. Bhatia S, et al. *J Immunother Cancer*. 2022;10(8):e004904. 7. Cowey CL, et al. *Future Oncol*. 2021;17(18):2339-2350. 8. Uhara H, et al. *J Dermatol*. 2024;51(4):475-483. 9. Bhanegaonkar A, et al. *Oncologist*. 2021;26(9):e1633-e1643. 10. Averbuch J, et al. *Cancer Med*. 2023;12(11):12065-12070. 11. Knott C, et al. Poster 1147P. Presented at ESMO Congress 2023, 20-24 October 2023; Madrid, Spain. 12. Becker JC, et al. Poster 1145P. Presented at ESMO Congress 2023, 20-24 October 2023; Madrid, Spain.

This material is intended for healthcare professionals only.

©2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. BAVENCIO is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates. DE-AVE-00912 06/25

Tafinlar® + Mekinist® in der adjuvanten Melanomtherapie

Wo Schutz beginnt, kann Leben weitergehen.^{a,1}

Schnell, stark und verlässlich^b bei BRAF-V600-positivem Melanom im Stadium III^{c,1-4}



Tafinlar
(dabrafenib)

+



Mekinist
(trametinib)

Pflichtangaben zu Tafinlar® + Mekinist®:



https://www.novartis.com/de-de/sites/novartis_de/files/428112_BT_Mekinist.pdf

 **NOVARTIS**

a 10-Jahres-Follow-up der COMBI-AD-Studie: Eine adjuvante Behandlung mit Tafinlar® + Mekinist® bei Melanom-Patient*innen im Stadium III mit einer BRAF-V600-Mutation war im Vergleich zu Placebo mit einem besseren rezidivfreien Überleben (48 % vs. 32 %; HR = 0,52; 95 %-KI: 0,43–0,63) sowie einem um 22 % reduzierten melanomspezifischen Sterberisiko verbunden (HR = 0,78; 95 %-KI: 0,59–1,02).¹ **b** Keine irreversiblen, langfristigen Nebenwirkungen nach dem 10-Jahres-Follow-up.¹ **c** Zur adjuvanten Behandlung von erwachsenen Melanom-Patient*innen im Stadium III mit einer BRAF-V600-Mutation nach vollständiger Resektion.^{3,4}

HR Hazard Ratio. **KI** Konfidenzintervall.

1. Long GV, et al. N Engl J Med. 2024;391(18):1709–1720. **2.** Dummer R, et al. N Engl J Med. 2020;383(12):1139–1148. **3.** Fachinformation Tafinlar. **4.** Fachinformation Mekinist.



HERACLIN

INSTITUT FÜR DATENMANAGEMENT
IM GESUNDHEITSWESEN GMBH

Data-Driven Oncology

Empowering biopharmaceutical innovation with comprehensive, real-world data-driven insights

Our Services

- Study design (Protocols, electronic case report forms (eCRFs), questionnaires, surveys)
- Definition of centers for recruitment and management
- Medical-scientific consulting
- Comprehensive study management
- Handling of regulatory submissions and approval processes
- IT infrastructure (electronic data capture, database services)
- Data collection and management
- Planning of biostatistical analyses and biostatistical evaluation
- Final reports, publications, medical writing
- Adverse event (AE)/Serious adverse event (SAE)/Adverse drug reaction (ADR)/Serious adverse drug reaction (SADR) management



Friedenstraße 58
15366 Neuenhagen bei Berlin

Telefon: +49 (0) 3342 42689-50
Fax: +49 (0) 3342 42689-60
info@heraclin.de
www.heraclin.de



Dermatologic Cooperative
Oncology Group
DeCOG

35th German Skin Cancer Congress

Congress programme out now
Early bird rate until Juli 10

DeCOG Annual Meeting
September 10–13, 2025

Essen Germany



An event of the Dermatologic Cooperative Oncology Group
of the German Cancer Society and the German Dermatological Society

www.ado-kongress.de

© Towseef, Gritik Creative - Stock Adobe.com

Mit Unterstützung der ADO



Arbeitsgemeinschaft
Dermatologische Onkologie
ADO

Dermato-Onkologie UPDATE 2026

20.–22.2.2026

Mercure Hotel MOA Berlin

HYBRID MEETING

**SAVE
THE
DATE**

22ND

EADO CONGRESS

April 23rd–25th, 2026

PRAGUE, CZECH REPUBLIC

O2 UNIVERSUM

SAVE THE DATE




ON-SITE CONGRESS WITH
ADDITIONAL VIRTUAL ACCESS

WWW.EADO2026.COM

Together into the future

*Plan with us your next
scientific event*



MedConcept Gesellschaft
für medizinische Projekte mbH
Friedenstraße 58, 15366 Neuenhagen



+49 3342 42689-30



info@medconcept.org



www.medconcept.org

MEDCONCEPT 
Experience since 1997

IMPORTANT INFORMATION

Internet Connection

Free Wi-Fi service will be available to all delegates within the Radisson Blu Hotel.

Certificate of Attendance:

All registered attendees will receive a certificate of attendance within 10 days after the meeting via e-mail and after completing an evaluation survey.

Please note! If you need to change your contact e-mail address, please come to the registration desk.

Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area.

Daily Scan

To receive your daily CME credits please remember to scan yourself once a day at the registration desk.
German participants must also register in the barcode list of the Bavarian Medical Association.

TED/Polling

Please scan the QR code with your mobile device or visit **www.slido.com** and enter the event code to participate in the polling.



event code
#EPCM_Main



event code
#EPCM_Parallel